- ●Neurocognitive deficits have been reported to hamper cognitive awareness.
- ●Awareness measured as the concordance of neurocognitive functioning and complaints.
- ●Patients divided in impaired and intact based on their neurocognitive performance.
- ●Three follow-up assessments every 12 weeks for a total of 36 weeks after baseline.
- ●Neurocognitive impaired patients with high-grade glioma (HGG) show signs of cognitive awareness.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Anderson SW, Tranel D. Awareness of disease states following cerebral infarction, dementia, and head trauma: standardized assessment. 2007;3:327–39. doi:〈10.1080/13854048908401482〉. Available from: 〈http://DxDoiOrg.vu-NlIdmOclcOrg/10.1080/13854048908401482〉.
- The neuropsychology of insight: impaired awareness of deficits in a psychiatric context.Psychiatr Ann. 1997; 27: 806-811https://doi.org/10.3928/0048-5713-19971201-10
- Cognitive awareness after treatment for high-grade glioma.Clin Neurol Neurosurg. 2021; : 210https://doi.org/10.1016/J.CLINEURO.2021.106953
- Awareness of disease states following cerebral infarction, dementia, and head trauma: standardized assessment.Clin Neuropsychol. 1989; 3: 327-339https://doi.org/10.1080/13854048908401482
- Interaction between memory impairment and depressive symptoms can exacerbate anosognosia: a comparison of Alzheimer’s disease with mild cognitive impairment.Aging Ment Health. 2019; 23: 595-601https://doi.org/10.1080/13607863.2018.1442411
- Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.Cancer. 2014; 120: 278-285https://doi.org/10.1002/CNCR.28369
- Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.Lancet. 2002; 360: 1361-1368https://doi.org/10.1016/S0140-6736(02)11398-5
- Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.Lancet Neurol. 2009; 8: 810-818https://doi.org/10.1016/S1474-4422(09)70204-2
- Cognitive deficits in adult patients with brain tumours.Lancet Neurol. 2004; 3: 159-168https://doi.org/10.1016/S1474-4422(04)00680-5
- Conceptualization of self-awareness in adults with acquired brain injury: a qualitative systematic review.Neuropsychol Rehabil. 2021; https://doi.org/10.1080/09602011.2021.1924794
- Metacognition and self-awareness in multiple sclerosis.Cortex. 2019; 111: 238-255https://doi.org/10.1016/J.CORTEX.2018.11.012
- Associations among measures of awareness of cognitive deficits in dementia.Alzheimer’s Dement. 2010; 6: 312-318https://doi.org/10.1016/J.JALZ.2009.06.005
- Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.Eur J Cancer. 2021; 144: 162-168https://doi.org/10.1016/J.EJCA.2020.10.040
- Lomustine and bevacizumab in progressive glioblastoma.N Engl J Med. 2017; 377: 1954-1963https://doi.org/10.1056/nejmoa1707358
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.Lancet Oncol. 2018; 19: 1170-1179https://doi.org/10.1016/S1470-2045(18)30362-0
- Lomustine and bevacizumab in progressive glioblastoma.N Engl J Med. 2017; 377: 1954-1963https://doi.org/10.1056/NEJMoa1707358
- The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol. 2007; 114: 97-109https://doi.org/10.1007/s00401-007-0243-4
- Hopkins verbal learning test – revised: normative data and analysis of inter-form and test-retest reliability.Clin Neuropsychol. 1998; 12: 43-55https://doi.org/10.1076/clin.126.96.36.1996
- Trail making test A and B: normative data stratified by age and education.Arch Clin Neuropsychol. 2004; 19: 203-214https://doi.org/10.1016/S0887-6177(03)00039-8
- Benton controlled oral word association test: reliability and updated norms. vol. 1. 1996
- Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.Neuro Oncol. 2011; 13: 660-668https://doi.org/10.1093/neuonc/nor024
- Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.Cancer. 2010; 116: 3348-3356https://doi.org/10.1002/cncr.25098
- Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. [Erratum appears in JAMA 1989 Nov 10;262(18):2542].JAMA. 1989; 262: 907-913
- Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.Eur J Cancer. 2021; 144: 162-168https://doi.org/10.1016/j.ejca.2020.10.040
- A guide to appropriate use of Correlation coefficient in medical research.Malawi Med J. 2012; 24: 69-71https://doi.org/10.4314/mmj.v24i3
- Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients.Qual Life Res. 2017; 26: 869-880https://doi.org/10.1007/s11136-016-1426-z
- Awareness of cognitive decline in patients with Alzheimer’s disease: a systematic review and meta-Analysis.Front Aging Neurosci. 2021; 13: 424https://doi.org/10.3389/FNAGI.2021.697234/BIBTEX
- Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma.Neuro-Oncol Pract. 2015; 2: 20-31https://doi.org/10.1093/nop/npu035
- Patient-rated versus proxy-rated cognitive and functional measures in older adults.Patient Relat Outcome Meas. 2017; 8: 33https://doi.org/10.2147/PROM.S126919
- Neurocognitive functioning following lung cancer treatment: the PRO-Long Study.Tech Innov Patient Support Radiat Oncol. 2022; 21: 36https://doi.org/10.1016/J.TIPSRO.2022.02.004
- Correlates of the discrepancy between objective and subjective cognitive functioning in non-demented patients with Parkinson’s disease.J Neurol. 2021; 268: 3444-3455https://doi.org/10.1007/S00415-021-10519-4/FIGURES/2
Hess C, Levy B, Hashmi AZ, Hogan J, Greenspan S, Elber A, et al. Subjective versus objective assessment of cognitive functioning in primary care. n.d. Available from: 〈https://doi.org/10.3122/jabfm.2020.03.190265〉.
- Discordance between subjective and objective evaluations of cognitive function in old Japanese patients with heart failure.Australas J Ageing. 2019; 38: 57-59https://doi.org/10.1111/AJAG.12591
- Selection bias in clinical trials.J Clin Oncol. 1985; 3: 1142-1147https://doi.org/10.1200/JCO.19188.8.131.522
- Self-reported awareness of performance in dementia.Cogn Brain Res. 2005; 25: 144-152https://doi.org/10.1016/j.cogbrainres.2005.05.001